研究论文开放获取
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. D’Addario, Martin Früh, Martin Reck, Pia Baumann, Walter Klepetko, Enriqueta Felip
Kantonsspital St. Gallen LungenClinic Grosshansdorf Karolinska University Hospital Karolinska Institutet
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
25130
17
18
19
20
2521
22
23
24
25
26
关键指标
323
被引次数 · OpenAlex
29.03
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 0.2%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
31
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
当前基于文献信息回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学Lung Cancer Diagnosis and Treatment
Lung Cancer Treatments and Mutations · Lung Cancer Research Studies
参考文献 31
A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer
被引 98Jingwei Jiang, Xiaohua Liang, Xinli Zhou · Lung Cancer · 2007
Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
被引 754Henrike E. Karim‐Kos, Esther de Vries, Isabelle Soerjomataram · European Journal of Cancer · 2008
Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007
被引 167Freddie Bray, Elisabete Weiderpass · International Journal of Cancer · 2009
此处列出前 3 条
引用本文 323
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
被引 1,552Yuankai Shi, Joseph S. K. Au, Sumitra Thongprasert · Journal of Thoracic Oncology · 2014
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
被引 626Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu · Journal of Clinical Oncology · 2013
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
被引 611Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu · The Lancet Oncology · 2012
按被引量排序，此处列出前 3 条